Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07482657
PHASE2

A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

Sponsor: Enanta Pharmaceuticals, Inc

View on ClinicalTrials.gov

Summary

Zelicapavir is a novel, orally administered, nonfusion replication inhibitor of RSV. It is being investigated in this Phase 2 study (EDP 938-203) as a potential treatment for RSV infection in both hospitalized and non-hospitalized children aged ≥28 days to ≤36 months who present with symptomatic RSV infection.

Official title: Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zelicapavir in Participants ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

Key Details

Gender

All

Age Range

28 Days - 36 Months

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2026-07

Completion Date

2026-12

Last Updated

2026-07-10

Healthy Volunteers

No

Interventions

DRUG

zelicapavir

Oral suspension

DRUG

Placebo

Placebo oral suspension to match zelicapavir

Locations (8)

Center of Excellence for Pediatric Infectious Diseases and Vaccines Faculty of Medicine, Chulalongkorn University (CE-PID)

Bangkok, Thailand

Nakornping Hospital

Chiang Mai, Thailand

Maharaj Nakorn Chiang Mai Hospital

Chiang Mai, Thailand

Chiangrai Prachanukroh Hospital

Chiang Rai, Thailand

Khon Kaen Hospital

Khon Kaen, Thailand

Lampang Hospital

Lampang, Thailand

Lamphun Hospital

Lamphun, Thailand

Maha Sarakham Hospital

Maha Sarakham, Thailand